Oracle Corp chart shows Death Cross, 50-day MA below 200-day MA. Hedge funds hold mixed positions, but technicals suggest ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Watch the Video How did Oracle go from market darling to market disappointment in just a few months? Lee and I agreed that the speed of the reversal surprised even seasoned investors. From AI royalty ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

As of 10:14:51 a.m. EST. Market Open.